There are many ways of generating revenue on the back of a successfully approved and patented treatment, after commercialisation. Many of which don't necessarilly mean a direct sales process from IHL to consumer. For example royalties generated and paid to us by other companies using our treatment as the gold standard approach.
There will never be a shortage of consumers in need of a GAD solution and that will require a very significant amount of therapists and companies globally providing treatment. Incannex if succesful will require many many parties using our approach and drugs across the globe due to sheer volume, all of which would be required to pay us for access.
